Severity of Lung Function Impairment Drives Transcriptional Phenotypes of COPD and Relates to Immune and Metabolic Processes

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD; 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed May 3, 2021.
   Google Scholar
• López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. doi:10.1111/resp.12660
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555. doi:10.1164/rccm.200703-456SO
   PubMed Web of Science ®Google Scholar
• Agusti A. The path to personalised medicine in COPD. Thorax. 2014;69(9):857–864. doi:10.1136/thoraxjnl-2014-205507
   PubMed Web of Science ®Google Scholar
• Corlateanu A, Mendez Y, Wang Y, Garnica RJA, Botnaru V, Siafakas N. Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art. Pulmonology. 2020;26(2):95–100. doi:10.1016/j.pulmoe.2019.10.006
   PubMed Web of Science ®Google Scholar
• Burgel PR, Paillasseur JL, Roche N. Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities. Biomed Res Int. 2014;2014:420134. doi:10.1155/2014/420134
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Endo-phenotyping of COPD patients. Expert Rev Respir Med. 2021;15(1):27–37. doi:10.1080/17476348.2020.1804364
   PubMed Web of Science ®Google Scholar
• Zeskind JE, Lenburg ME, Spira A. Translating the COPD transcriptome: insights into pathogenesis and tools for clinical management. Proc Am Thorac Soc. 2008;5(8):834–841. doi:10.1513/pats.200807-074TH
   PubMedGoogle Scholar
• Wheelock CE, Goss VM, Balgoma D, et al. Application of ‘omics technologies to biomarker discovery in inflammatory lung diseases. Eur Respir J. 2013;42(3):802–825. doi:10.1183/09031936.00078812
   PubMed Web of Science ®Google Scholar
• Spira A, Beane J, Pinto-Plata V, et al. Gene expression profiling of human lung tissue from smokers with severe emphysema. Am J Respir Cell Mol Biol. 2004;31(6):601–610. doi:10.1165/rcmb.2004-0273OC
   PubMed Web of Science ®Google Scholar
• Golpon HA, Coldren CD, Zamora MR, et al. Emphysema lung tissue gene expression profiling. Am J Respir Cell Mol Biol. 2004;31(6):595–600. doi:10.1165/rcmb.2004-0008OC
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Srisuma S, DeMeo DL, et al. Molecular biomarkers for quantitative and discrete COPD phenotypes. Am J Resp Cell Mol Biol. 2009;40:359–367. doi:10.1165/rcmb.2008-0114OC
   PubMedGoogle Scholar
• Jeong I, Lim JH, Oh DK, Kim WJ, Oh YM. Gene expression profile of human lung in a relatively early stage of COPD with emphysema. Int J Chron Obstruct Pulmon Dis. 2018;13:2643–2655. doi:10.2147/COPD.S166812
   PubMed Web of Science ®Google Scholar
• Samaha E, Vierlinger K, Weinhappel W, et al. Expression profiling suggests loss of surface integrity and failure of regenerative repair as major driving forces for chronic obstructive pulmonary disease progression. Am J Respir Cell Mol Biol. 2021;64(4):441–452. doi:10.1165/rcmb.2020-0270OC
   PubMedGoogle Scholar
• Faner R, Morrow JD, Casas-Recasens S, et al. Do sputum or circulating blood samples reflect the pulmonary transcriptomic differences of COPD patients? A multi-tissue transcriptomic network META-analysis. Respir Res. 2019;20(1):5. doi:10.1186/s12931-018-0965-y
   PubMedGoogle Scholar
• Seo M, Qiu W, Bailey W, et al. Genomics and response to long-term oxygen therapy in chronic obstructive pulmonary disease. J Mol Med. 2018;96(12):1375–1385. doi:10.1007/s00109-018-1708-8
   PubMed Web of Science ®Google Scholar
• Bahr TM, Hughes GJ, Armstrong M, et al. Peripheral blood mononuclear cell gene expression in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2013;49(2):316–323. doi:10.1165/rcmb.2012-0230OC
   PubMed Web of Science ®Google Scholar
• Morrow JD, Qiu W, Chhabra D, et al. Identifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methods. BMC Med Genomics. 2015;8:1. doi:10.1186/s12920-014-0072-y
   PubMedGoogle Scholar
• Singh D, Bassi M, Balzano D, et al. COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type-2 and PDE4 gene expression in sputum. J Cell Mol Med. 2021;25(2):905–918. doi:10.1111/jcmm.16146
   PubMed Web of Science ®Google Scholar
• Govoni M, Bassi M, Vezzoli S, et al. Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis. Respir Res. 2020;21(1):72. doi:10.1186/s12931-020-1329-y
   PubMedGoogle Scholar
• Baines KJ, Wright TK, Gibson PG, Powell H, Hansbro PM, Simpson JL. Azithromycin treatment modifies airway and blood gene expression networks in neutrophilic COPD. ERJ Open Res. 2018;4(4):00031–02018. doi:10.1183/23120541.00031-2018
   PubMedGoogle Scholar
• Ricci F, Bassi M, McGeough CM, Jellema GL, Govoni M. A Novel Processing-Free Method for RNAseq analysis of spontaneous sputum in chronic obstructive pulmonary disease. Front Pharmacol. 2021;12:704969. doi:10.3389/fphar.2021.704969
   PubMedGoogle Scholar
• Ditz B, Sarma A, Kerstjens HAM, et al. The sputum transcriptome better predicts COPD exacerbations after the withdrawal of inhaled corticosteroids than sputum eosinophils. ERJ Open Res. 2021;7(3):00097–2021. doi:10.1183/23120541.00097-2021
   PubMedGoogle Scholar
• Baines KJ, Negewo NA, Gibson PG, et al. A sputum 6 gene expression signature predicts inflammatory phenotypes and future exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1577–1590. doi:10.2147/COPD.S245519
   PubMed Web of Science ®Google Scholar
• Begg M, Hamblin JN, Jarvis E, et al. Exploring PI3Kδ molecular pathways in stable COPD and following an acute exacerbation, two randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2021;16(16):1621–1636. doi:10.2147/COPD.S309303
   PubMedGoogle Scholar
• Singh D, Fox SM, Tal-Singer R, et al. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax. 2011;66(6):489–495. doi:10.1136/thx.2010.153767
   PubMed Web of Science ®Google Scholar
• Nikolaou V, Massaro S, Fakhimi M, Stergioulas L, Price D. COPD phenotypes and machine learning cluster analysis: a systematic review and future research agenda. Respir Med. 2020;171:106093. doi:10.1016/j.rmed.2020.106093
   PubMed Web of Science ®Google Scholar
• Simpson JL, Powell H, Baines KJ, et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS One. 2014;9(8):e105609. doi:10.1371/journal.pone.0105609
   PubMed Web of Science ®Google Scholar
• McDonald VM, Higgins I, Wood LG, Gibson PG. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68(7):691–694. doi:10.1136/thoraxjnl-2012-202646
   PubMed Web of Science ®Google Scholar
• Simpson JL, McDonald VM, Baines KJ, et al. Influence of age, past smoking, and disease severity on TLR2, neutrophilic inflammation, and MMP-9 levels in COPD. Mediators Inflamm. 2013;2013:462934. doi:10.1155/2013/462934
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.581
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321–1327. doi:10.1164/ajrccm/145.6.1321
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med. 1995;152(3):1107–1136. doi:10.1164/ajrccm.152.3.7663792
   PubMed Web of Science ®Google Scholar
• Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428–1446. doi:10.1183/09031936.00150314
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa021322
   PubMed Web of Science ®Google Scholar
• Gibson PG, Wlodarczyk JW, Hensley MJ, et al. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med. 1998;158(1):36–41. doi:10.1164/ajrccm.158.1.9705031
   PubMedGoogle Scholar
• Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11(1):54–61. doi:10.1111/j.1440-1843.2006.00784.x
   PubMed Web of Science ®Google Scholar
• McDonald VM, Simpson JL, Higgins I, Gibson PG. Multidimensional assessment of older people with asthma and COPD: clinical management and health status. Age Ageing. 2011;40(1):42–49. doi:10.1093/ageing/afq134
   PubMed Web of Science ®Google Scholar
• Baines KJ, Simpson J, Wood L, Scott R, Gibson PG. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J Allergy Clin Immunol. 2011;127(1):153–160. doi:10.1016/j.jaci.2010.10.024
   PubMed Web of Science ®Google Scholar
• Burgel PR, Paillasseur JL, Peene B, et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One. 2012;7(12):e51048. doi:10.1371/journal.pone.0051048
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Gómez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430–437. doi:10.1136/thx.2010.154484
   PubMed Web of Science ®Google Scholar
• Castaldi PJ, Dy J, Ross J, et al. Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. Thorax. 2014;69(5):415–422. doi:10.1136/thoraxjnl-2013-203601
   PubMed Web of Science ®Google Scholar
• Groth EE, Weber M, Bahmer T, et al. Exploration of the sputum methylome and omics deconvolution by quadratic programming in molecular profiling of asthma and COPD: the road to sputum omics 2.0. Respir Res. 2020;21(1):274. doi:10.1186/s12931-020-01544-4
   PubMedGoogle Scholar
• Kurian N, Cohen TS, Öberg L, et al. Dual role for A MEK inhibitor as a modulator of inflammation and host defense mechanisms with potential therapeutic application in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:2611–2624. doi:10.2147/COPD.S211619
   PubMed Web of Science ®Google Scholar
• Titz B, Sewer A, Schneider T, et al. Alterations in the sputum proteome and transcriptome in smokers and early-stage COPD subjects. J Proteomics. 2015;128:306–320. doi:10.1016/j.jprot.2015.08.009
   PubMed Web of Science ®Google Scholar
• Waithman J, Moffat JM, Patterson NL, van Beek AE, Mintern JD. Antigen Presentation. In: Reference Module in Biomedical Sciences. Elsevier; 2014.
   Google Scholar
• Holling TM, Schooten E, van Den Elsen PJ. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum Immunol. 2004;65(4):282–290. doi:10.1016/j.humimm.2004.01.005
   PubMedGoogle Scholar
• Benoit ME, Clarke EV, Morgado P, Fraser DA, Tenner AJ. Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. J Immunol. 2012;188(11):5682–5693. doi:10.4049/jimmunol.1103760
   PubMed Web of Science ®Google Scholar
• Akata KA-O, Yamasaki K, Leitao Filho FS, et al. Abundance of non-polarized lung macrophages with poor phagocytic function in Chronic Obstructive Pulmonary Disease (COPD). Biomedicines. 2020;8(10):398. doi:10.3390/biomedicines8100398
   PubMedGoogle Scholar
• Yuan X, Chang CY, You R, et al. Cigarette smoke-induced reduction of C1q promotes emphysema. JCI Insight. 2019;4(13). doi:10.1172/jci.insight.124317
   Google Scholar
• Hiemstra PS. Altered macrophage function in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10:S180–185. doi:10.1513/AnnalsATS.201305-123AW
   PubMedGoogle Scholar
• Bouhlel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6(2):137–143. doi:10.1016/j.cmet.2007.06.010
   PubMed Web of Science ®Google Scholar
• Lea S, Plumb J, Metcalfe H, et al. The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD. Eur Respir J. 2014;43(2):409–420. doi:10.1183/09031936.00187812
   PubMed Web of Science ®Google Scholar
• Lee SY, Lee HS, Park HW. Transcriptome analysis of sputum cells reveals two distinct molecular phenotypes of “asthma and chronic obstructive pulmonary disease overlap” in the elderly. Eur J Med Res. 2022;27(1):215. doi:10.1186/s40001-022-00861-2
   PubMedGoogle Scholar
• Yang HY, Hu LY, Chen HJ, Chen RY, Hu CK, Shen CC. Increased risk of chronic obstructive pulmonary disease in patients with hyperlipidemia: a nationwide population-based cohort study. Int J Environ Res Public Health. 2022;19(19):12331.
   PubMedGoogle Scholar
• Kothapalli D, Liu S-L, Bae Yong H, et al. Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. Cell Rep. 2012;2(5):1259–1271. doi:10.1016/j.celrep.2012.09.018
   PubMedGoogle Scholar
• Kerr ID, Haider AJ, Gelissen IC. The ABCG family of membrane-associated transporters: you don’t have to be big to be mighty. Br J Pharmacol. 2011;164(7):1767–1779. doi:10.1111/j.1476-5381.2010.01177.x
   PubMedGoogle Scholar
• Chai AB, Ammit AJ, Gelissen IC. Examining the role of ABC lipid transporters in pulmonary lipid homeostasis and inflammation. Respir Res. 2017;18(1):41. doi:10.1186/s12931-017-0526-9
   PubMedGoogle Scholar